Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/16/2026

Hepatitis C Treatment Guidelines

  • The American Association for the Study of Liver Diseases recommends sofosbuvir/velpatasvir for 8 weeks as a first-line option for patients with recently acquired hepatitis C 1
  • The American Association for the Study of Liver Diseases recommends glecaprevir/pibrentasvir for 8 weeks as an alternative first-line option for recently acquired hepatitis C 1
  • Treatment for chronic hepatitis C should be selected based on genotype, prior treatment history, and presence of cirrhosis, according to the American Association for the Study of Liver Diseases 1

Pre-Treatment Assessment

  • The American Association for the Study of Liver Diseases recommends HCV RNA quantitative assay and genotyping/subgenotyping prior to initiating antiviral treatment 2
  • Assessment of liver disease severity is essential before starting treatment to guide therapy decisions and predict prognosis, as stated by the American Association for the Study of Liver Diseases 2
  • Evaluation for potential drug-drug interactions with all concurrent medications is necessary, according to the European Association for the Study of the Liver 3

Treatment Monitoring

  • The American Association for the Study of Liver Diseases recommends HCV RNA or HCV core antigen detection at 12 weeks post-treatment (SVR12) to assess treatment success 1
  • For most patients on DAA regimens with expected high SVR rates, checking SVR is optional except in patients at risk of reinfection, as stated by the American Association for the Study of Liver Diseases 1
  • Monitoring for adverse effects is important, though newer DAA regimens have significantly fewer side effects than older interferon-based therapies, according to the European Association for the Study of the Liver 3

Special Populations

  • The American Association for the Study of Liver Diseases recommends treatment initiation as soon as possible in patients with advanced fibrosis (F3-F4) 4, 5

Hepatitis C Cure with Direct-Acting Antiviral Therapy

Introduction to HCV Cure

  • Hepatitis C can be cured in almost all infected patients (>97%) following the advent of direct-acting antiviral (DAA) medications, according to the Journal of Hepatology guidelines 6, 7
  • A sustained virological response (SVR), defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion, represents a cure of the infection in more than 99% of patients, as recommended by the Journal of Hepatology 8

Treatment Options and Efficacy

  • The introduction of all-oral DAA regimens has revolutionized HCV treatment, allowing virtually all patients to achieve SVR regardless of HCV genotype or disease stage, as stated by the Journal of Hepatology 7
  • Current DAA treatments have replaced older interferon-based therapies that had lower efficacy and more side effects, according to the Journal of Hepatology guidelines 9, 8
  • FDA-approved DAA combinations include ombitasvir/paritaprevir/ritonavir and grazoprevir/elbasvir combinations, which have been shown to be effective in treating HCV, as reported by the Journal of Hepatology 10

Post-Treatment Considerations

  • After achieving SVR, patients without advanced fibrosis generally have excellent outcomes with resolution of liver disease, as noted by the Journal of Hepatology 8
  • Patients with cirrhosis who achieve SVR still require monitoring as they remain at risk for complications, though at significantly reduced rates, according to the Journal of Hepatology guidelines 6, 11
  • The risk of hepatocellular carcinoma (HCC) and all-cause mortality is significantly reduced, but not eliminated, in cirrhotic patients who achieve SVR, as reported by the Journal of Hepatology 8
  • Patients with complete response to HCC therapy who achieve SVR require indefinite post-SVR HCC surveillance via ultrasound every 6 months, as recommended by the Journal of Hepatology 11

Cure and Surveillance in Hepatitis C

Definition of Cure

  • Sustained virologic response (SVR12), defined as undetectable HCV RNA 12 weeks after treatment completion, represents a virologic cure in more than 99% of patients, according to the American Gastroenterological Association 12, 13
  • Fewer than 1% of patients relapse after achieving SVR12, making this endpoint tantamount to permanent viral eradication, as reported by the American Gastroenterological Association 12, 13

Risk of Hepatocellular Carcinoma

  • The risk of HCC is significantly reduced but not eliminated in cirrhotic patients who achieve SVR, with a relevant residual risk of 0.3–2.4% annually, as noted by the European Association for the Study of the Liver 14
  • Meta-analyses of interferon-based therapies showed more than 70% reduction in HCC incidence after SVR, but patients with liver cirrhosis still retain a relevant residual risk, according to the European Association for the Study of the Liver 14

Post-Treatment Confirmation of Cure

  • SVR should be confirmed by undetectable HCV RNA at 12 weeks after completion of DAA treatment, as recommended by the American Gastroenterological Association 13
  • Routine confirmation of SVR at 48 weeks post-treatment is recommended, though testing at 24 weeks should be considered on an individual basis, according to the American Gastroenterological Association 13
  • Routine testing for HCV RNA beyond 48 weeks after end of treatment to evaluate for late virologic relapse is not supported by available evidence, as reported by the American Gastroenterological Association 13

Post‑treatment Management of HCV‑Antibody Positive Patients

Confirming Virologic Cure

  • Quantitative HCV RNA testing using a highly sensitive assay (detection limit ≤15–50 IU/mL) should be performed to verify cure status after prior therapy. AASLD guideline. 15, 16
  • Achieving an undetectable HCV RNA level 12 weeks after treatment (SVR12) corresponds to virologic cure in > 99 % of patients. AASLD guideline. 15
  • Relapse after SVR12 occurs in < 1 % of patients, making SVR12 effectively equivalent to permanent viral eradication. AASLD guideline. 15

Surveillance After Sustained Virologic Response

Patients with Advanced Fibrosis (F3) or Cirrhosis

  • Lifelong hepatocellular carcinoma (HCC) surveillance with abdominal ultrasound ± AFP every 6 months is recommended. AASLD guideline. 15
  • An initial endoscopic screening for esophagogastric varices is advised for all cirrhotic patients regardless of SVR; if no varices or only small varices are found, repeat endoscopy every 2–3 years. AASLD guideline. 15

Patients with Mild Fibrosis (F0–F2)

  • No HCC surveillance is required after SVR in patients with fibrosis stage F0–F2. AASLD guideline. 15

Monitoring for Reinfection

  • Routine HCV RNA testing beyond 48 weeks post‑treatment is not indicated unless the patient has ongoing risk factors (e.g., ongoing injection drug use). AASLD guideline. 15
  • For high‑risk groups (people who inject drugs, men who have sex with men), annual HCV RNA testing is recommended to detect possible reinfection. AASLD guideline. 15

Pre‑Retreatment Assessment (When HCV RNA Is Detectable)

  • Screen for hepatitis B infection (HBsAg and anti‑HBc) before retreatment to assess reactivation risk. AASLD guideline. 15
  • Confirm HCV genotype if it has not been previously documented, as genotype influences retreatment regimen selection. AASLD guideline. 16

Common Pitfalls (Cited)

  • Anti‑HCV antibody testing should not be used to determine cure status because antibodies persist lifelong after infection. AASLD guideline. 15
  • HCC surveillance must be continued in cirrhotic patients after SVR; the risk of HCC, although reduced by > 70 %, is not eliminated. AASLD guideline. 15
  • Treatment failure should not be assumed without confirming detectable HCV RNA; the vast majority of treated patients achieve cure. AASLD guideline. 15

REFERENCES

← Return to Home